Suppr超能文献

p38丝裂原活化蛋白激酶抑制可改善小鼠顺铂肾毒性。

p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice.

作者信息

Ramesh Ganesan, Reeves W Brian

机构信息

Division of Nephrology, Pennsylvania State College of Medicine, Hershey, PA 17033, USA.

出版信息

Am J Physiol Renal Physiol. 2005 Jul;289(1):F166-74. doi: 10.1152/ajprenal.00401.2004. Epub 2005 Feb 8.

Abstract

Cisplatin is an important chemotherapeutic agent but can cause acute renal injury. Part of this acute renal injury is mediated through tumor necrosis factor-alpha (TNF-alpha). The pathway through which cisplatin mediates the production of TNF-alpha and injury is not known. Cisplatin activates p38 MAPK and induces apoptosis in cancer cells. p38 MAPK activation leads to increased production of TNF-alpha in ischemic injury and in macrophages. However, little is known concerning the role of p38 MAPK in cisplatin-induced renal injury. Therefore, we examined the effect of cisplatin on p38 MAPK activity and the role of p38 MAPK in mediating cisplatin-induced TNF-alpha production and renal injury. In vitro, cisplatin caused a dose-dependent activation of p38 MAPK in proximal tubule cells. Inhibition of p38 MAPK activation led to inhibition of TNF-alpha production. In vivo, mice treated with a single dose of cisplatin (20 mg/kg body wt) developed severe renal dysfunction at 72 h [blood urea nitrogen (BUN): 154 +/- 34 mg/dl, creatinine: 1.4 +/- 0.4 mg/dl], which was accompanied by an increase in kidney p38 MAPK activity and an increase in infiltrating leukocytes. However, animals treated with the p38 MAPK inhibitor SKF-86002 along with cisplatin showed less renal dysfunction (BUN: 55 +/- 14 mg/dl, creatinine: 0.3 +/- 0.02 mg/dl, P < 0.05), less severe histological damage, and fewer leukocytes compared with cisplatin+vehicle-treated animals. Serum levels of TNF-alpha, sTNFRI, and sTNFRII also increased significantly in cisplatin-treated mice compared with SKF-86002-treated mice (P < 0.05). Kidney mRNA levels of TNF-alpha were significantly increased in cisplatin-treated mice compared with either SKF-86002- or saline-treated animals. The hydroxyl radical scavenger DMTU (100 mg.kg body wt(-1).day(-1)) prevented the activation of p38 MAPK by cisplatin both in vitro and in vivo. DMTU also completely prevented cisplatin-induced renal injury (BUN: 140 +/- 27 vs. 22 +/- 2 mg/dl, P < 0.005) and the increase in serum TNF-alpha (33 +/- 7 vs. 4 +/- 2 pg/ml, P < 0.005) and kidney TNF-alpha mRNA in vivo. We conclude that hydroxyl radicals, either directly or indirectly, activate p38 MAPK and that p38 MAPK plays an important role in mediating cisplatin-induced acute renal injury and inflammation, perhaps through production of TNF-alpha.

摘要

顺铂是一种重要的化疗药物,但可导致急性肾损伤。这种急性肾损伤部分是通过肿瘤坏死因子-α(TNF-α)介导的。顺铂介导TNF-α产生和损伤的途径尚不清楚。顺铂可激活p38丝裂原活化蛋白激酶(p38 MAPK)并诱导癌细胞凋亡。p38 MAPK激活导致缺血性损伤和巨噬细胞中TNF-α产生增加。然而,关于p38 MAPK在顺铂诱导的肾损伤中的作用知之甚少。因此,我们研究了顺铂对p38 MAPK活性的影响以及p38 MAPK在介导顺铂诱导的TNF-α产生和肾损伤中的作用。在体外,顺铂在近端小管细胞中引起p38 MAPK的剂量依赖性激活。抑制p38 MAPK激活导致TNF-α产生受到抑制。在体内,单次给予顺铂(20 mg/kg体重)的小鼠在72小时时出现严重肾功能不全[血尿素氮(BUN):154±34 mg/dl,肌酐:1.4±0.4 mg/dl],同时伴有肾p38 MAPK活性增加和浸润白细胞增多。然而,与顺铂+溶剂处理的动物相比,用p38 MAPK抑制剂SKF-86002和顺铂联合处理的动物肾功能不全较轻(BUN:55±14 mg/dl,肌酐:0.3±0.02 mg/dl,P<0.05),组织学损伤较轻,白细胞较少。与SKF-86002处理的小鼠相比,顺铂处理的小鼠血清TNF-α、可溶性TNF受体I(sTNFRI)和可溶性TNF受体II(sTNFRII)水平也显著升高(P<0.05)。与SKF-86002处理或生理盐水处理的动物相比,顺铂处理的小鼠肾TNF-α mRNA水平显著升高。羟自由基清除剂二甲基硫脲(DMTU,100 mg·kg体重-1·天-1)在体外和体内均能阻止顺铂对p38 MAPK的激活。DMTU还完全预防了顺铂诱导的肾损伤(BUN:140±27 vs. 22±2 mg/dl,P<0.005)以及体内血清TNF-α升高(33±7 vs. 4±2 pg/ml,P<0.005)和肾TNF-α mRNA增加。我们得出结论,羟自由基直接或间接激活p38 MAPK,并且p38 MAPK在介导顺铂诱导的急性肾损伤和炎症中起重要作用,可能是通过TNF-α的产生。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验